MorphoSys AG (ETR:MOR – Get Free Report)’s stock price traded up 0.1% during trading on Thursday . The company traded as high as €67.80 ($73.70) and last traded at €67.80 ($73.70). 18,595 shares changed hands during trading, a decline of 88% from the average session volume of 153,687 shares. The stock had previously closed at €67.75 ($73.64).
MorphoSys Stock Up 0.1 %
The company has a market cap of $2.56 billion, a PE ratio of -12.26, a P/E/G ratio of 0.06 and a beta of 0.60. The firm has a 50-day simple moving average of €67.76 and a two-hundred day simple moving average of €62.74. The company has a debt-to-equity ratio of 3,454.18, a current ratio of 1.38 and a quick ratio of 3.49.
MorphoSys Company Profile
MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity.
Featured Stories
- Five stocks we like better than MorphoSys
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Why Call Options Volume for These 2 Stocks Spiked Together
- Learn Technical Analysis Skills to Master the Stock Market
- MarketBeat Week in Review – 7/22 – 7/26
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.